Pharmacologic management of psychosis in dementia

Journal of Clinical Psychiatry

Volumn 60, Issue SUPPL. 8, 1999, Pages 54-60

  Schneider, Lon S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETOPHENAZINE; ACETOPHENAZINE DIMALEATE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; LOXAPINE; LOXAPINE SUCCINATE; MOLINDONE; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE;

AGGRESSION; AGITATION; BEHAVIOR THERAPY; DELUSION; DEMENTIA; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; HALLUCINATION; HUMAN; NEUROBIOLOGY; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

AGED; ANTIPSYCHOTIC AGENTS; CLOZAPINE; COMORBIDITY; DELUSIONS; DEMENTIA; HALLUCINATIONS; HUMANS; PSYCHOTIC DISORDERS; RISPERIDONE; TREATMENT OUTCOME;

EID: 0032964964     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Tariot PN, Blazina L. The psychopathology of dementia. In: Morris JC, ed. Handbook of Dementing Illnesses. New York, NY: Marcel Dekker; 1994: 461-475
2. Ferris SH, Steinberg G, Shulman E, et al. Institutionalization of Alzheimer's patients: reducing precipitating factors through family counseling. Arch Foundation Thanatology 1985;12:7
3. Chui HC, Lyness SA, Sobel E, et al. Extrapyramidal signs and psychiatric symptoms predict faster cognitive decline in Alzheimer's disease. Arch Neurol 1994;51:676-681
4. Stern Y, Liu X, Albert M, et al. Modeling the influence of extrapyramidal signs on the progression of Alzheimer's disease. Arch Neurol 1996;53: 1121-1126
5. Zubenko GS, Moossy J, Martinez AJ, et al. Neuropathologic and neurochemical correlates of psychosis in primary dementia. Arch Neurol 1991; 48:619-624
6. Lawlor BA, Ryan TM, Bierer LM, et al. Lack of association between clinical symptoms and postmortem indices of brain serotonin function in Alzheimer's disease [letter]. Biol Psychiatry 1995;37:895-896
7. Sunderland T, Molchan SE, Little JT, et al. Pharmacologic challenges in Alzheimer disease and normal controls: cognitive modeling in humans. Alzheimer Dis Assoc Disord 1997;11(suppl 4):S23-S26
8. Cummings JL, Gorman DG, Shapira J. Physostigmine ameliorates the delusions of Alzheimer's disease. Biol Psychiatry 1993;33:536-541
9. Kaufer DI, Cummings JL, Christine D. Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study. J Geriatr Psychiatry Neurol 1996;9:1-6
10. Bodick NC, Offen WW, Levey AI, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer's disease. Arch Neurol 1997;54:465-473
11. Raskind MA. Psychopharmacology of noncognitive abnormal behaviors in Alzheimer's disease. J Clin Psychiatry 1998;59(suppl 9):28-32
12. Starkstein SE, Vazquez S, Petracca G, et al. A SPECT study of delusions in Alzheimer's disease. Neurology 1994;44:2055-2059
13. Mentis MJ, Weinstein EA, Horwitz B, et al. Abnormal brain glucose metabolism in the delusional misidentification syndromes: a positron emission tomography study in Alzheimer's disease. Biol Psychiatry 1995;38: 438-449
14. Sultzer DL, Mahler ME, Mandelkern MA, et al. The relationship between psychiatric symptoms and regional cortical metabolism in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 1995;7:476-484
15. Russo-Neustadt A, Cotman CW. Adrenergic receptors in Alzheimer's disease brain: selective increases in the cerebella of aggressive patients. J Neurosci 1997;17:5573-5580
16. Raskind MA, Peskind ER. Neurobiologie bases of noncognitive behavioral problems in Alzheimer disease. Alzheimer Dis Assoc Disord 1994;8(suppl 3):54-60
17. Peskind ER, Wingerson D, Murray S, et al. Effects of Alzheimer's disease and normal aging on cerebrospinal fluid norepinephrine responses to yohimbine and clonidine. Arch Gen Psychiatry 1995;52:774-782
18. Drach LM, Steinmetz HE, Wach S, et al. High proportion of dementia with Lewy bodies in the postmortems of a mental hospital in Germany. Int J Geriatr Psychiatry 1997;12:301-306
19. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. Neurology 1996; 47:1113-1124
20. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
21. Horwitz G, Tariot PN, Mead K, et al. Discontinuation of antipsychotics in nursing home patients with dementia. Am J Geriatr Psychiatry 1995;3: 290-299
22. Borison RL. Recent advances in the pharmacotherapy of schizophrenia. Harv Rev Psychiatry 1997;4:255-271
23. Keck PE, McElroy SL. The new antipsychotics and their therapeutic potential. Psychiatr Ann 1997;27:320-331
24. Miller CH, Mohr F, Umbricht D, et al. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J Clin Psychiatry 1998;59:69-75
25. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of schizophrenia. J Clin Psychopharmacol 1993;13:25-40
26. Zyprexa [package insert]. Indianapolis, Ind: Eli Lilly & Company; 1997
27. Clozaril [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 1997
28. Seroquel [package insert]. Wilmington, Del: Zeneca Pharmaceuticals; 1997
29. McManus DQ, Arvanitis LA, Kowalcyk BB, and the Seroquel Trial 48 Study Group. Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. J Clin Psychiatry. In press
30. Zarate CA Jr, Baldessarini RJ, Siegel AJ, et al. Risperidone in the elderly: a pharmacoepidemiologic study. J Clin Psychiatry 1997;58:311-317
31. Wirshing DA, Spellberg BJ, Erhard SM, et al. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998;44:778-783
32. Perkins DO. Weight gain and the new antipsychotics. J Psychotic Disord 1998;2:8-9
33. Schneider LS, Pollock VE, Lyness SA. A meta-analysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 1990;38:553-563
34. Oberholzer AF, Hendriksen C, Monsch AU, et al. Safety and effectiveness of low-dose clozapine in psychogeriatric patients: a preliminary study. Int Psychogeriatr 1992;4:187-195
35. Salzman C, Vaccaro B, Lieff J, et al. Clozapine in older patients with psychosis and behavioral disruption. Am J Geriatr Psychiatry 1995;3:26-33
36. Lieberman JA, Alvir JMJ. A report of clozapine-induced agranulocytosis in the United States. Drug Saf 1992;7:1-2
37. Goldberg RJ, Goldberg J. Risperidone for dementia-related disturbed behavior in nursing home residents: a clinical experience. Int Psychogeriatr 1997;9:65-68
38. Workman RH Jr, Orengo CA, Bakey AA, et al. The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease. J Neuropsychiatry Clin Neurosci 1997;9:594-597
39. Lavretsky H, Sultzer D. A structured trial of risperidone for the treatment of agitation in dementia. Am J Geriatr Psychiatry 1998;6:127-135
40. Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry 1999;60:107-115
41. Arvanitis LA, Miller BG, and the Seroquel Trial 13 Study Group. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233-246
42. Abse DW, Dahlstrom WG, Hill C. The value of chemotherapy in senile mental disturbance. JAMA 1960;174:2036-2042
43. Hamilton LD, Bennett JL. The use of trifluoperazine in geriatric patients with chronic brain syndrome. J Am Geriatr Soc 1962;10:140-147
44. Hamilton LD, Bennett JL. Acetophenazine for hyperactive geriatric patients. Geriatrics 1962;17:596-601
45. Sugarman AA, Williams BH, Adlerstein AM. Haloperidol in the psychiatric disorders of old age. Am J Psychiatry 1964;120:1190-1192
46. Rada RT, Kellner R. Thiothixene in the treatment of geriatric patients with chronic organic brain syndrome. J Am Geriatr Soc 1976;3:105-107
47. Petrie WM, Ban TA, Berney S. Loxapine in psychogeriatrics: a placebo- and standard-controlled clinical investigation. J Clin Psychopharmacol 1982;2:122-126
48. Barnes R, Veith R, Okimoto J. Efficacy of antipsychotic medications in behaviorally disturbed dementia patients. Am J Psychiatry 1982;139: 1170-1174